Cost of product revenue of $1,900,000 included $900,000 of obsolete inventory costs. Research and development expenses of $1,200,000 in the fourth quarter of twenty twenty four decreased versus the fourth quarter of twenty twenty three by $4,200,000 primarily driven by a $2,100,000 decrease of clinical trial costs related to VP315 as well as costs related to increased headcount of $1,200,000 and a decrease in regulatory costs of $700,000 For the full year 2024, research and development expenses were $11,800,000 compared to $20,300,000 for the year ended 12/31/2023. The decrease of $8,500,000 was primarily attributable to reductions of costs related to WiCan preapproval activity of $3,800,000 and decreased clinical costs for VP315 of $3,100,000 Selling, general and administrative expenses of $10,000,000 in the fourth quarter of twenty twenty four decreased versus the fourth quarter of twenty twenty three by $6,800,000 reflecting our commercial realignment activity and realization of cost savings. For the full year 2024, selling, general and administrative expenses were $58,800,000 compared to $47,300,000 for the year ended 12/31/2023. The increase of $11,500,000 was primarily a result of higher expenses related to commercial activities for Wycanth for the treatment of molluscum, including increased compensation, recruiting fees, benefits and travel due to ramp up of sales force of $8,500,000 as well as increased commercial related costs of $5,100,000 GAAP net loss was $16,200,000 or $0.24 per share for the fourth quarter of twenty twenty four compared to a GAAP net loss of $24,600,000 or $0.53 per share for the fourth quarter of twenty twenty three.